Literature DB >> 2066356

Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice.

G Arancia1, C Leonetti, W Malorni, C Greco, G Formisano, M Marangolo, G Zupi.   

Abstract

The effects of the combination of N-methylformamide (NMF) with 5-fluorouracil (5-FU) on tumor growth and morphological features of human colon carcinoma cells (HT29) implanted in nude mice were assessed. Both agents were administered i.p. at tolerable doses: 5-FU at 19 mg/kg for 5 days and NMF at 200 mg/kg for 12 days. Four main schedules were tested: 5-FU alone, NMF alone, NMF followed by 5-FU and 5-FU followed by NMF. The last sequence was the most effective, as compared with the other treatment regimens. In particular, the 5-FU----NMF combination induced a tumor inhibition of about 75% at the end of the treatments (17th day) versus an inhibition of 23%-43% in the other schedules. Morphological observations, carried out by light and electron microscopy, indicated a possible relationship between the presence of structural changes and tumor growth inhibition. The results of this study renew interest in the use of NMF in sequential combination confirming sequence as a critical factor for the optimal combination of NMF and 5-FU.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066356     DOI: 10.1007/BF01630719

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  31 in total

1.  Phase II trial of N-methylformamide for advanced renal cell carcinoma.

Authors:  C N Sternberg; A Yagoda; H I Scher; P Hollander
Journal:  Cancer Treat Rep       Date:  1986-05

2.  Phase I trial of N-methylformamide in pediatric patients with refractory leukemias.

Authors:  S B Murphy; J Mirro; C H Pui; C B Pratt
Journal:  Cancer Treat Rep       Date:  1987-12

Review 3.  Differentiation modifiers.

Authors:  P A Marks; R A Rifkind
Journal:  Cancer       Date:  1984-12-01       Impact factor: 6.860

4.  N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy.

Authors:  S P Langdon; J A Hickman; A Gescher; M F Stevens; D Chubb; L M Vickers
Journal:  Eur J Cancer Clin Oncol       Date:  1985-06

5.  N-methylformamide-mediated enhancement of in vitro tumor cell chemosensitivity.

Authors:  P J Tofilon; C M Vines; L Milas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line.

Authors:  G Zupi; M Marangolo; G Arancia; C Greco; N Laudonio; F Iosi; G Formisano; W Malorni
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

7.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

8.  Ultrastructural evidence of dimethylformamide-induced differentiation of cultured human colon carcinoma cells. Increased expression of desmosomes.

Authors:  T G Christensen; B Burke; D L Dexter; N Zamcheck
Journal:  Cancer       Date:  1985-10-01       Impact factor: 6.860

9.  Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide.

Authors:  L A Ferrari; S F Bliven; M Wiemann; P Calabresi; A S Glicksman; J T Leith
Journal:  Cancer Treat Rep       Date:  1986-10

10.  N-methylformamide: antitumour activity and metabolism in mice.

Authors:  A Gescher; N W Gibson; J A Hickman; S P Langdon; D Ross; G Atassi
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

View more
  2 in total

Review 1.  Animal models in pediatric surgery.

Authors:  A Mortell; S Montedonico; P Puri
Journal:  Pediatr Surg Int       Date:  2005-12-06       Impact factor: 1.827

2.  Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.

Authors:  D Del Bufalo; C Cucco; C Leonetti; G Citro; I D'Agnano; M Benassi; T Geiser; G Zon; B Calabretta; G Zupi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.